BACKGROUND: Patients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc-APAH) experience higher mortality rates than patients with idiopathic disease and those with other connective tissue diseases (CTD-APAH). We sought to identify unique predictors of mortality associated with SSc-APAH in the CTD-APAH population. METHODS: The Registry to Evaluate Early and Long-Term PAH Management (REVEAL Registry) is a multicenter, prospective US-based registry of patients with previously and newly diagnosed (enrollment within 90 days of diagnostic right-sided heart catheterization) PAH. Cox regression models evaluated all previously identifi ed candidate predictors of mortality in the overall REVEAL Registry population t...
BACKGROUND: Pulmonary arterial hypertension (PAH) is the leading cause of mortality in patients with...
Objective: Earlier detection of pulmonary arterial hypertension (PAH), a leading cause of death in s...
International audienceObjective Patients with systemic sclerosis and both pulmonary hypertension and...
AbstractBACKGROUND:Patients with pulmonary arterial hypertension (PAH) associated with systemic scle...
BACKGROUND: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in systemic sclero...
Objectives: To describe the survival rate in a cohort of systemic sclerosis (SSc) patients with pulm...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/106105/1/acr22121.pd
BACKGROUND: In this study, we investigated the impact of the new haemodynamic definition of pulmonar...
Introduction Pulmonary arterial hypertension (PAH) is a major cause of mortality in connective tissu...
BACKGROUND: Pulmonary arterial hypertension (PAH) is a major cause of morbidity and mortality in pat...
Background: In this study, we investigated the impact of the new haemodynamic definition of pulmonar...
Pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) has been poo...
Pulmonary arterial hypertension (PAH) is a pro-gressively fatal disorder that affects patients inde-...
Background: Pulmonary arterial hypertension (PAH) is the leading cause of death in systemic sclerosi...
BACKGROUND: Pulmonary arterial hypertension (PAH) is the leading cause of death in systemic sclerosi...
BACKGROUND: Pulmonary arterial hypertension (PAH) is the leading cause of mortality in patients with...
Objective: Earlier detection of pulmonary arterial hypertension (PAH), a leading cause of death in s...
International audienceObjective Patients with systemic sclerosis and both pulmonary hypertension and...
AbstractBACKGROUND:Patients with pulmonary arterial hypertension (PAH) associated with systemic scle...
BACKGROUND: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in systemic sclero...
Objectives: To describe the survival rate in a cohort of systemic sclerosis (SSc) patients with pulm...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/106105/1/acr22121.pd
BACKGROUND: In this study, we investigated the impact of the new haemodynamic definition of pulmonar...
Introduction Pulmonary arterial hypertension (PAH) is a major cause of mortality in connective tissu...
BACKGROUND: Pulmonary arterial hypertension (PAH) is a major cause of morbidity and mortality in pat...
Background: In this study, we investigated the impact of the new haemodynamic definition of pulmonar...
Pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) has been poo...
Pulmonary arterial hypertension (PAH) is a pro-gressively fatal disorder that affects patients inde-...
Background: Pulmonary arterial hypertension (PAH) is the leading cause of death in systemic sclerosi...
BACKGROUND: Pulmonary arterial hypertension (PAH) is the leading cause of death in systemic sclerosi...
BACKGROUND: Pulmonary arterial hypertension (PAH) is the leading cause of mortality in patients with...
Objective: Earlier detection of pulmonary arterial hypertension (PAH), a leading cause of death in s...
International audienceObjective Patients with systemic sclerosis and both pulmonary hypertension and...